Celyad Oncology SA · EURONEXT:CYAD
Celyad Oncology SA — SITC 2018
9 slides from Celyad Oncology SA's conference presentation, Nov 9, 2018
Slide 1: CYAD-101: A first non-gene edited allogeneic CAR T cell
November 9, 2018 SITC 2018 CYAD-101: A first non-gene edited allogeneic CAR T cell
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation may contain forward-looking statements, including statements regarding the safety and efficacy of CYAD-01 and the new mAb manufacturing method used to manufacture this drug product candidate; statements concerning the ongoing and planned clinical develo
Slide 3: CYAD-101: A non-gene edited allogeneic CAR T cell using TIM technology
CYAD-101: A non-gene edited allogeneic CAR T cell using TIM technology Donor Patient GvHD TCR Va Vb CD3δ CD3ε CD3ε CD3γ Ca Cb Healthy tissues - - ++ +- - CD3ζ CD3ζ ITAMs TIM TIM 3 S I T C 2 0 1 8 – C Y A D - 1 0 1
Slide 4: CYAD-101: an allogeneic CAR T cell based on NKG2D receptor
CYAD-101: an allogeneic CAR T cell based on NKG2D receptor • Retroviral transduction of : • TCR inhibitory molecule (TIM) TIM incorporating TCR complex NKG2D CAR • Co-expression of a Second generation CAR using endogenous DAP10 as co-stimulator 4 S I T C 2 0 1 8 – C Y A D - 1 0 1
Slide 5: TIM impairs CYAD-101 CAR T alloreactivity in vitro and in vivo
TIM impairs CYAD-101 CAR T alloreactivity in vitro and in vivo OKT3 TCR activation ** CYAD-101 0 .8 0 .6 IF N - ( n g / m l) 0 .4 0 .2 0 .0 C T R (t C D 1 9 ) C Y A D -101 100 P e r c e n t s u r v iv a l *** 50 C T R (tC D 1 9 ) NSG mice (n=9) C Y A D -10 1 0 0 20 40 60 D a y s a f t e r in je c
Slide 6: CYAD-101 is potent against NKG2D ligands expressing tumour in vivo
CYAD-101 is potent against NKG2D ligands expressing tumour in vivo 0.2x106 10x106 10x106 10x106 HCT116 CYAD-101 CYAD-101 CYAD-101 D0 D7 D14 D21 *** 1 .5 1 0 1 1 C T R (tC D 1 9 ) 100 C Y A D -10 1 n=12 ) 2 (p h o t o n s / s e c / m m 1 0 1 1 B io lu m in e s c e n c e P e r c e n t s u r v iv a l
Slide 7: Future of CYAD-101
Future of CYAD-101 • CYAD-101 CAR T cells • Inhibition of GvHD • Effective CAR activity • Phase I clinical study • Second generation allogeneic platform based on shRNAs (P220) 7 S I T C 2 0 1 8 – C Y A D - 1 0 1
Slide 8: Thank you! Abstract Poster Number: P213
Thank you ! Abstract Poster Number: P213 CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule Poster location: Hall E Poster presentation hours: Friday, Nov. 9, from 12:45 – 2:15 p.m. and 6:30 – 8 p.m. Contact Follow us investors@celyad.com Twitter : @CelyadSA • Linkedin
Slide 9: Contact
Contact Follow us investors@celyad.com Twitter : @CelyadSA • Linkedin : @Celyad